← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Johnson & Johnson grew sales and rebuilt earnings, but cash flow was flat and leverage moved up.
The read at a glance✓ Audited against SEC data
- Growth — +6.0% revenue to $94.19BOK
- Profitability — Net income +90.6% to $26.80BOK
- Cash quality — Free cash flow -0.7% to $19.70BNote
- Margins — Gross margin -119 bps; net margin +1262 bpsNote
- Balance sheet — Debt +27.9%; equity +14.1%Watch
- Insiders — 1 open-market buy / 21 sellsNote
Business
Johnson & Johnson is a global healthcare company organized around Innovative Medicine and MedTech. Innovative Medicine covers oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. MedTech covers surgery, orthopaedics, cardiovascular, and vision.
Where the revenue comes from
Fiscal 2025, as JOHNSON & JOHNSON reports it. History and quarterly detail are in the app.
- Innovative Medicine$60.4B
- MedTech$33.8B
- Pharmaceutical$670.0M
Leadership changes
From JOHNSON & JOHNSON's own filings, the day they're filed.
- Daniel Pinto · director · appointmenteff. 2025-07-01
- Peter M. Fasolo · President · departureeff. 2024-10-01
- Ashley McEvoy · President · departureeff. 2023-10-20
Latest filings
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-28
- 10-Q · Quarterly report2026-07-23
- 8-K · Company announcement2026-07-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about JOHNSON & JOHNSON, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.